about
Diagnostic, prognostic and therapeutic role of CD30 in lymphoma.Multiple cutaneous lymphoproliferative disorders showing a retained tumor clone by T-cell receptor gene rearrangement analysis: a case series of four patients and review of the literature.Prognostic significance of CD30 expression in nasal natural killer/T-cell lymphoma.Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.CD25+ folliculotropic Sézary syndrome with CD30+ large cell transformation.Targeting CD30 in malignant tissues: challenges in detection and clinical applications.CD30 as a therapeutic target for lymphoma.Peripheral T-cell and NK cell lymphoproliferative disorders: cell of origin, clinical and pathological implications.New variant lymphomatoid papulosis type E preceding and coexisting with mycosis fungoides - a case report and review of the literature.Lymphomatoid Papulosis in Children and Adolescents: A Systematic Review.New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.Brentuximab vedotin in CD30+ cutaneous lymphoma: How do we treat - How shall we treat? A review of the literature.Contribution of longitudinal follow up and clinical pathological correlation in the diagnosis CD30-positive skin infiltrates.CD30 expression in peripheral T-cell lymphomas.Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis: An Analysis of Phase 2 Results.Not bitten by the bug: A CD30+ lymphoproliferative disorder masquerading as arthropod bites.Lymphomatoid papulosis: A cutaneous lymphoproliferative disorder in a patient on fingolimod for multiple sclerosis.Primary cutaneous CD30(+) lymphoproliferative disorders.
P2860
Q30240160-9B4E17B2-E3F9-44A6-9F7E-33FE9A051BBAQ30278864-CD710C82-41FD-4347-BB73-98F96C989C66Q33598637-D97F6949-8202-4EC4-9BD4-1D77808AFB89Q36534677-0D20042B-AA19-4FE0-BA6E-0584C67CB25CQ38063343-98E750EC-A1C6-4546-80D8-E4DC336D1E8EQ38108134-48DC2376-C711-4A70-9548-AD14D1A18F7CQ38138482-5F34CC12-C930-4C5B-B161-2F6139CF02DFQ38289038-CF9B4B00-54E0-46FE-84A7-3BBB5EA05BD7Q38566478-467EAC68-905C-423C-BCEF-511A5AA9F811Q38823698-E390BA7A-E618-4C90-82D0-24C7E0A3D73DQ38896683-5DD9101D-3823-4B5F-A70B-57791256EE7AQ39432325-906B63F9-B3C5-49D0-B6B1-48482E6BAB5DQ40990296-04275825-DC0C-45F9-81D3-D5344D133D99Q43065880-98084A7D-7E81-43BB-AD1A-97734CFE0977Q47251529-4764CB6B-E425-45B4-AE36-2B518DF78275Q48141458-DA85FBF5-5C07-440A-ACB0-F9A5D8BDDCBDQ52927685-CCB91415-DE0C-486A-A2AB-6C085149B47CQ54629950-D651E0EA-6FE6-4B47-8ED3-B87E845EF8F1
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
CD30+ neoplasms of the skin.
@en
CD30+ neoplasms of the skin.
@nl
type
label
CD30+ neoplasms of the skin.
@en
CD30+ neoplasms of the skin.
@nl
prefLabel
CD30+ neoplasms of the skin.
@en
CD30+ neoplasms of the skin.
@nl
P2860
P1476
CD30+ neoplasms of the skin.
@en
P2093
Madeleine Duvic
P2860
P2888
P304
P356
10.1007/S11899-011-0096-8
P577
2011-12-01T00:00:00Z